Lupin Gets USFDA Nod for Generic Diabetes Drug Dapagliflozin

Mumbai-based drugmaker Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) for its generic Dapagliflozin tablets, strengthening its presence in the diabetes treatment market.

The approval covers Dapagliflozin tablets in 5 mg and 10 mg strengths. These are used to improve blood sugar control in adults with type 2 diabetes. Lupin’s product is a generic equivalent of Farxiga, a widely used drug for managing diabetes globally.

The clearance was granted under the Abbreviated New Drug Application (ANDA) pathway. This means Lupin’s version has been found to be therapeutically equivalent to the original drug in terms of safety, effectiveness, and quality. Patients can expect the same results as the branded medicine, but usually at a lower cost, boosting access to affordable medicines.

This approval is an important step for Lupin as it expands its offerings in the U.S. pharmaceutical market, one of the largest healthcare markets globally. The demand for diabetes medication continues to rise due to increasing lifestyle-related diseases, making this a key growth area.

Dapagliflozin belongs to a class of drugs known as SGLT2 inhibitors. These medicines work by helping the body remove excess sugar through urine, thereby lowering blood glucose levels. They are also increasingly being used for additional health benefits, including heart and kidney protection.

Also Read: Sanofi's Lunsekimig Shows Promise in Respiratory Disease Trials

With this launch, Lupin is expected to face competition from other generic drug manufacturers, but the overall opportunity remains strong. The growing demand reflects a rising global diabetes market driven by awareness and diagnosis.

Following the announcement, Lupin’s shares saw a positive response, reflecting investor confidence and continued growth in the pharmaceutical industry.

Overall, this approval highlights Lupin’s focus on expanding its global generics portfolio while improving access to essential treatments.